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Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with an estimated
prevalence of 10–20%. Current understanding of the pathophysiology of IBS is incomplete
due to the lack of a clearly identified pathological abnormality and due to the lack of reli-
able biomarkers. Possible mechanisms believed to contribute to IBS development and IBS
like symptoms include physical stressors, such as infection or inflammation, psychological,
and environmental factors, like anxiety, depression, and significant negative life events.
Some of these mechanisms may involve the brain-gut axis (BGA). In this article we review
the current knowledge on the possible involvement of the BGA in IBS and discuss new
directions for potential future therapies of IBS.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI)
disorder with an estimated prevalence of 10–20% (Philpott et al.,
2011). According to Thompson et al. (2000) it accounts for about
3% of all general practice and up to 40% of all GI referrals. IBS
causes considerable morbidity amongst its sufferers, who manifest
with abdominal pain and altered stool consistency and frequency
(Drossman and Dumitrascu, 2006; Lee et al., 2007; Adeyemo et al.,
2010). Although not life-threatening, it is a heavy economic bur-
den due to increased work absenteeism and impaired quality of
life of its sufferers, as well as increased use of health care services
(Sandler et al., 2002).
Current understanding of the pathogenesis of IBS is unsatisfac-
tory due to the lack of demonstrable pathological abnormalities
and reliable biomarkers. Traditionally, IBS has been considered
a purely functional disorder. A hypothesis based on specimens
obtained at endoscopy and in serological cytokine studies views
IBS as a localized low grade inflammatory disorder with mast cells
(MC) playing a particularly important role (Mayer and Collins,
2002; Philpott et al., 2011). An alternative hypothesis states that
food allergy may be responsible (Atkinson et al., 2004). Most
recently, the relationship between the neural and immunological
networks within the gut and the bi-directional communication
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between the gut and the central nervous system (CNS), often
related to as the brain-gut axis (BGA) attract most attention
(Collins and Bercik, 2009).
In this review we focus on the disturbances in the BGA as a
plausible cause of IBS. We overview the pathophysiological mech-
anisms contributing to symptom perception and generation and
the endogenous systems involved. Particular attention is given to
stress, emotion and psychological factors in the IBS pathogenesis.
We also discuss new directions for potential future therapies of IBS
based on discussed mechanisms.
THE BRAIN-GUT AXIS
The BGA constitutes the enteric nervous system (ENS) and the gut
wall in the periphery, the CNS, and the hypothalamo-pituitary-
adrenal (HPA) axis (Collins and Bercik, 2009). The bi-directional
communication between the gut and the CNS is based on the
neural, endocrine and neuroimmune pathways. Neuronal path-
ways include afferent fibers originating in the dorsal root of the
ganglia of the thoracic spinal cord (T1–T10) projecting to inte-
grative cortical areas, such as the cerebral, anterior and posterior
cingulate, insular, and amygdala cortices and efferent fibers to
smooth muscle and glands, originating in nuclei within the brain-
stem, as well as S2–S4 spinal levels (parasympathetic) and in the
lateral horn of the thoraco-lumbar spinal cord (T1–L3; sympa-
thetic; Mulak and Bonaz, 2004; Gaman and Kuo, 2008; O’Mahony
et al., 2011). The main pain signaling pathways in the BGA are
the spinothalamic tracts and dorsal columns with descending
supraspinal afferents originating from the rostral ventral medulla
(Gaman and Kuo, 2008).
In physiological conditions, signals from the GI tract influence
the brain, which in turn can exert changes in motility, secretion,
and immune function (Mayer et al., 2006). The axis is therefore an
important communication system for healthy regulation of food
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intake, digestion, gut sensations, and control of the bowel move-
ments. Structural and functional disruptions in the BGA cause
changes in perceptual and reflexive responses of the nervous sys-
tem and may lead to GI disorders, including IBS, which often
comorbid with chronic psychiatric diseases (Clarke et al., 2009;
Gros et al., 2009).
STRUCTURAL AND FUNCTIONAL ABNORMALITIES IN THE CENTRAL
NERVOUS SYSTEM
Visceral hypersensitivity is a key mechanism underlying abdom-
inal pain, one of the main symptoms of IBS (Azpiroz et al.,
2007; Barbara et al., 2011). Visceral hypersensitivity is thought
to be determined by central and peripheral mechanisms, as it
may result from altered transmission within the gut wall, the
spinal cord, or the brain. However, the specific contribution of
the BGA components to hypersensitive responses in IBS remains
unclear.
Direct imaging techniques were recently employed to detect
the abnormalities in the structure and functioning of the brain
and their possible implications in the pathology of IBS. There
is only one structural magnetic resonance imaging (MRI) study
(Davis et al., 2008), in which the thinning in the anterior mid-
cingulate and insular cortex, structures important for perception
of internal body states were observed in the IBS patients. These
results were later confirmed by functional MRI (Blankstein et al.,
2010). Although the underlying cause of cortical thinning was
not elucidated, factors like decreased cell size, apoptosis of neural
cells, death of glia and astrocytes, fewer dendritic spines, reduced
synaptic density, and excitotoxicity related to enhanced glutamate
signaling were suggested as possible contributors. Seminowicz
et al. (2010) reported morphometric brain differences between
female IBS patients and controls in terms of regional increases
and decreases in gray matter density. These alterations occurred
primarily in brain areas involved in attention and emotion modu-
lation, as well as cortico-limbic pontine pain modulatory systems
and in networks processing interoceptive information. Further
studies of Blankstein et al. (2010) evidenced increased gray matter
density in the hypothalamus of the IBS patients. Currently it is
not possible to discern whether these changes are a predisposing
factor for IBS or a secondary change after sustained visceral signals
(Fukudo and Kanazawa, 2011).
In their excellent paper on imaging techniques used in the stud-
ies of brain-gut interactions, Rapps et al. (2008) reviewed the
possible central mechanisms implicated in IBS and found pub-
lished reports somewhat contradictory. The region that attracted
most attention was the anterior cingulate cortex (ACC), one of
the six most commonly reported cortical areas that display pain-
evoked activity during acute stimulation in humans (Chen et al.,
2011). ACC showed altered activity during rectal stimulation in
IBS patients in comparison to healthy controls (Rapps et al., 2008
and citations therein). Interestingly, although greater pain by rec-
tal balloon distension was reported by the IBS patients with a
history of sexual or physical abuse, changes in their ACC activity
were less pronounced than in other IBS patients and the controls
(Ringel, 2002). In line with these observation was the study of
Mertz et al. (2000), who demonstrated differential activation of
the brain between IBS patients and controls. The ACC, the insula,
the prefrontal cortex, and the thalamus were more activated in the
IBS patients as compared with healthy controls and the pattern
was related to the experience of individuals.
Hall et al. (2010) revealed differences in the central responses
in health and in IBS to a single ramp-tonic distension of the colon
across a distributed network of regions, involving sensory, striatal,
limbic, and frontal areas. The IBS participants showed heightened
activation of the ACC, suggesting increased affective responses to
painful visceral stimuli. However, it was also observed that the acti-
vation of the thalamic, striatal, and dorsolateral prefrontal cortex
(DLPFC) regions was relatively greater in control subjects, as com-
pared to IBS patients, which may reflect increased ascending input
to the brain, in particular to the cortex and a heightened arousal
reaction to distension. Greater recruitment of the DLPFC by con-
trols than IBS patients is consistent with the notion of abnormal
descending modulation in IBS.
To further explore the central mechanisms of visceral hyper-
sensitivity in IBS, Lawal et al. (2006) examined total cortical
recruitment in response to subliminal (sub-conscious) stepped
changes in distension pressure and observed that visceral hyper-
sensitivity in IBS patients is due to increased afferent signaling
to the brain, rather than altered processing at the level of the
brain. However, the results of the study were later questioned,
among others by Lackner et al. (2006), who showed that cog-
nitive behavioral therapy in IBS patients is associated with a
reduction of baseline activity in the ACC and accompanied by
improvements of GI symptoms. Dorn et al. (2007) showed a
contributory part of neurosensitivity in the form of enhanced
activity with central neural networks independent of cognitive
function.
The most novel findings of Chen et al. (2011) showing that the
patients with IBS have white matter abnormalities in the insula,
ACC, and other brain areas associated with pain, interoception,
and homeostasis indicate that functional gray matter abnormali-
ties in IBS patients are accompanied by white matter aberrations.
The white matter deficiencies of the descending modulation of
pain and dysfunction of the medial pain system may be responsible
for the emotional aspect of pain in IBS.
In conclusion, as evidenced by the results of the meta-
analysis performed by Tillisch et al. (2011), a greater engage-
ment of regions associated with emotional arousal and endoge-
nous pain modulation, but similar activation of regions involved
in processing of visceral afferent information was observed in
patients with IBS compared to controls. These results support
a role for structural and functional abnormalities in the CNS
in IBS.
COGNITIVE–BEHAVIORAL MODEL OF IBS
IBS is often considered a bio-psychosocial disorder (Engel, 1977;
Camilleri and Choi, 1997; Drossman, 1998), which suggests that
psychological (e.g., emotions, cognitions, and behavior), social
(e.g., modeling, support), and physiological (e.g., cramps, bloat-
ing) factors may induce and exacerbate its symptoms (Toner et al.,
1998; Mach, 2004). Individual cognitive and emotional responses
to recurrent GI symptoms and associated life events may also affect
the therapeutical efficacy of anti-IBS treatments (Kennedy et al.,
2012).
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CENTRAL MECHANISMS
Abnormal activity within higher-order brain systems may alter
cognitive and affective processes and contribute to both abnormal
pain regulation and higher levels of anxiety and depression,
typically reported in chronic pain conditions (Ribeiro et al.,
2005) and IBS (Piche et al., 2011, and citations therein). The
cognitive-behavioral model of IBS is focused particularly on emo-
tional arousal and organism response to stress and the integrated
network of structures, which include the hypothalamus, amyg-
dala, and periaqueductal gray (PAG), as well as a number of
neuromodulators and hormones.
Greenwood-Van et al. (2001) showed in animal models that
there is a link between the central pathways mediating stress and
anxiety and the mechanisms regulating the GI sensitivity. A key
component of this link is the amygdala, which is known for its role
in the regulation of emotional behavior and the expression of fear
and anxiety. Further studies in rodents demonstrated that colonic
sensitivity and motility are increased following fear conditioning
(Gue et al., 1991; Tyler et al., 2007). In accordance, studies on IBS
patients showed substantial activation of the hypothalamus and
amygdala, as well as decreased activity of the antinociceptive PAG
(Naliboff et al., 2001). More recent investigations employing rec-
tosigmoid balloon distension in IBS patients have shown increased
activity in the amygdala, insula, cingulate, and prefrontal cortex,
which form a network of brain structures involved in regulating
affective and sensory processes (Naliboff et al., 2003; Wilder-Smith
et al., 2004; Myers and Greenwood-Van, 2009).
ROLE OF ANS AND HPA AXIS
The autonomic nervous system (ANS) and the hypothalamus-
pituitary-adrenal (HPA) axis are commonly regarded as the major
components of the stress response system in the vertebrates. Alter-
ations of this complex system have been linked to a variety of
anxiety-related psychiatric disorders and stress-sensitive pain syn-
dromes. Stress and stress-related psychosocial factors have also
been proposed to act in IBS, particularly its post-infectious variety
(PI-IBS), by overarching inflammation and the BGA (Arborelius
et al., 1999; Gwee et al., 1999; Fukudo, 2007; Spiller and Garsed,
2009).
The correct function of the ANS and its cross-talk with CNS are
important factors preventing from IBS. Disturbances at the ANS
level, indicated by decreased parasympathetic and increased sym-
pathetic activity and altered autonomic reflexes often occur in the
IBS patients and account for the level of perception to GI stimuli
and extra-intestinal symptoms (Azpiroz, 2002; Jarrett et al., 2003;
Spaziani et al., 2008).
The key activator of the HPA axis is corticotrophin-releasing
factor (CRF),an endogenous 41-amino acid neuropeptide secreted
from endocrine cells in the paraventricular nucleus (PVN) of the
hypothalamus (Aguilera et al., 2008). The action of CRF is medi-
ated by the CRF1 and CRF2 receptors, which belong to the G
protein-coupled receptor family (Kostich et al., 1998). CRF recep-
tor activity can also be modulated by other peptides, like urocortins
(UCN; Bale and Vale, 2004; Tache and Brunnhuber, 2008). In the
mammalian brain three urocortins have been identified: UCN I,
which binds to both receptors, and UCN II and UCN III, selectively
binding to CRF2 receptor (Morin et al., 1999; Hsu and Hsueh,
2001; Lewis et al., 2001; Reyes et al., 2001; Bale and Vale, 2004;
Dautzenberg et al., 2004). However, the neuroendocrine, auto-
nomic, and behavioral responses to fear and stress are mediated
exclusively by CRF and UCN I, which are selective CRF1 receptor
ligands (Vale et al., 1981; Bale and Vale, 2004; Tache et al., 2009;
Chen et al., 2011).
Corticotrophin-releasing factor and UCN I initiate the signal-
ing cascade in the HPA axis by stimulating the anterior pitu-
itary to secrete adrenocorticotropic hormone (ACTH), which in
turn induces synthesis and secretion of glucocorticoids from the
adrenal cortex. Growing evidence suggests that also the extra-
hypothalamic CRF system is poised to play a critical role in both
psychiatric and the BGA disorders (Lowry and Moore, 2006; Bravo
et al., 2011).
In rodents, stress-induced release or exogenous administration
of CRF and UCN I increased anxiety-like behaviors and stimu-
lated colonic secretion, intestinal motility, and visceral sensitivity
(Moreau et al., 1997; Slawecki et al., 1999; Saunders et al., 2002;
Vetter et al., 2002; Million et al., 2003; Martinez et al., 2004;
Tache et al., 2004, 2009). Johnson et al. (2010) provided evi-
dence that elevated corticosterone levels affected the amygdala
and significantly increased brain activation in response to colorec-
tal distension (CRD) compared to that seen in cholesterol-treated
controls. Elevated CRF expression was found in the thalamus of the
rats exposed to neonatal maternal separation (Tjong et al., 2010).
Deletion of the CRF1 gene using transgenic models or intraven-
tricularly administered CRF1 antagonists had anxiolytic effects
and attenuated stress- and CRF-induced alterations in gastric and
colonic motor function (Smith et al., 1998; Million et al., 2003;
Martinez and Tache, 2006; Trimble et al., 2007).
Only a limited number of studies in IBS patients measured
basal and stimulated HPA axis hormone levels in response to meal,
hormone challenge, or mental stress (Chang et al., 2009, and cita-
tions therein) and some of them demonstrated increased HPA
axis responses in IBS compared to controls. Fukudo et al. (1998)
observed that the intravenous injection of CRF in IBS patients
induced exaggerated motility of the colon and increased visceral
pain sensitivity compared with healthy controls, whereas admin-
istration of a non-selective CRF receptor antagonist ameliorated
these responses (Lembo et al., 1996; Sagami et al., 2004). The recent
study by Chang et al. (2009) showed that basal levels of plasma
ACTH were significantly decreased, while both 24 h basal plasma
cortisol levels and stress-induced cortisol levels were mildly ele-
vated upon visceral stimulation in female IBS patients compared
to controls, suggesting a dysregulation of the HPA axis in IBS.
However, the role of the observed dysregulation of HPA axis in
modulating IBS severity or abdominal pain remained unclear.
A meta-analysis performed by Tillisch et al. (2011) revealed that
the central nucleus of amygdala indirectly activates the HPA axis
and increases ACTH and glucocorticoid secretion via subcorti-
cal regions, which relay on PVN (Redgate and Fahringer, 1973;
Feldman and Weidenfeld, 1998; Herman et al., 2003; Shepard
et al., 2003). The CRF-dependent involvement of the amygdala
in the induction of anxiety-like behavior, visceral hypersensi-
tivity, altered bowel habits and other common feature of IBS
has been later confirmed in animal studies (Tache et al., 2002;
Myers and Greenwood-Van, 2007, 2010; Venkova et al., 2010).
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The hippocampus may also be involved in several aspects relevant
to the IBS symptomatology, e.g., pain, anxiety, and stress (Prado
and Roberts, 1985; Bannerman et al., 2004; Kwan et al., 2005;
McEwen, 2007; Niddam et al., 2011). Saito et al. (2002) demon-
strated that the induction of visceral pain by CRD increased the
release of hippocampal noradrenaline in animal models. Niddam
et al. (2011) observed abnormal hippocampal glutamatergic neu-
rotransmission in IBS patients and inverse correlation between
glutamate-glutamine concentrations and emotional stress indica-
tors, which was not observed in healthy individuals. It remains pos-
sible that the observed hippocampal glutamatergic hypofunction
could result from a generally impaired HPA axis tone or it could
represent compensatory mechanisms of adaption to enhanced
glucocorticoid feedback.
PSYCHOSOCIAL FACTORS AND IBS
According to the cognitive-behavioral model, a history of abuse
and other psychosocial factors may induce and aggravate symp-
toms of IBS, influence illness experience, and affect treatment
outcome.
Ringel et al. (2008) showed that patients with IBS and a his-
tory of abuse had a significantly lower pain and urge thresholds
and a greater tendency to report pain in response to aversive rec-
tal distentions compared with patients with IBS or abuse history
alone. However, neuro-sensory sensitivity remained unchanged.
These observations suggest that the abuse history in IBS patients
may affect central mechanisms of pain amplification or regional
brain activation at sites linked to affect and attention, resulting in
heightened awareness to visceral and somatic symptoms, greater
pain reports, and greater clinical behavioral responses to painful
visceral stimuli. Nevertheless, changes in peripheral signaling by
nociceptive DRG neurons, including those innervating the colon
cannot be excluded, as suggested by several animal studies (Khasar
et al., 2008; Winston et al., 2010).
It was also observed that there is a higher prevalence of psy-
chological and psychiatric disorders observed in IBS patients:
depression, somatization disorder, generalized anxiety disorder,
panic, and phobic disorders and coping difficulties (for review see,
Arebi et al., 2008). Drossman et al. (1999) estimated that up to 70%
of the patients referred to tertiary centers with IBS meet diagnos-
tic criteria for anxiety or depression. However, Elsenbruch et al.
(2006) revealed that women with IBS were characterized by an
exaggerated anticipatory anxiety response at baseline, but essen-
tially unaltered anxiety and neuroendocrine responses to a public
speaking stressor. These results would suggest that IBS patients
show essentially normal emotional responses when faced with
challenging psychosocial situations.
Although well-evidenced, the impact of psychosocial factors on
the neurochemical responsiveness of visceral nociceptive pathways
and the physiological function of the GI remains unclear. It is pos-
sible that the psychosocial stressors and/or stressful early life events
modulate the immune response of the gut to infectious agents
and cause low level inflammation and mast cell infiltration and
degranulation in the bowel (Barbara et al., 2004; Ohman and Sim-
ren, 2010; Chen et al., 2011; Philpott et al., 2011). This is supported
by questionnaire-based studies indicating an increased prevalence
of atopic diseases among IBS patients (Philpott et al., 2011, and
citations therein) and a report published by Barbara et al. (2004),
demonstrating that there is an increased number of degranulating
MC in patients with IBS compared to that in the healthy con-
trols. Increased mucosal immune activation and elevated blood
concentrations in pro-inflammatory cytokines are also believed to
impact the CNS functioning (for review see; Kennedy et al., 2012).
Although these large molecules do not freely pass the blood-brain
barrier, a number of studies have provided substantial evidence
for their central mechanisms of action, sympathetic arousal and
the HPA axis activation (Dinan et al., 2006).
In rodents, early life stress in the form of separation of neonates
from the mother results in permanent changes in the CNS, which
include unrestrained secretion of CRF and increased expression of
its receptors (Owens and Nemeroff, 1993), increased regional nor-
epinephrine release (Southwick et al., 1999), downregulation of β-
receptors,decreased benzodiazepine receptor,andγ-aminobutryic
acid type A receptor (Caldji et al., 2000). A significant increase in
5-HT-positive cell number and 5-HT content after CRD stimula-
tion was also observed in the colon of animals, which experienced
maternal separation (Ren et al., 2007). Videlock et al. (2009)
demonstrated that IBS patients and controls with a history of
early adverse life events (EAL) have a greater cortisol response to a
visceral stressor compared to individuals without EAL, suggesting
the involvement of the HPA axis.
CURRENT AND FUTURE MOLECULAR TARGETS FOR IBS
TREATMENT
Various classes of drugs, like 5-HT3 antagonists, tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs),
gabapentinoids, CRF-1 antagonists, β3 adrenoceptor agonists,
somatostatin,N -methyld-aspartate receptor antagonists, or mela-
tonin are currently in use for the treatment of visceral analgesia
and other symptoms of IBS. However, new molecular targets for
the future IBS therapeutics are also being investigated.
SEROTONIN RECEPTORS
Serotonin (5-HT) is a key neurotransmitter and a signaling mol-
ecule that plays an important role in sensation, secretion, and
absorption (for review see, Gershon and Tack, 2007; Garvin and
Wiley, 2008). A number of studies reported altered serotonergic
signaling activity in the brain and gut in IBS, including increase
in plasma 5-HT in IBS-D (diarrhea-predominant) and PI-IBS,
reduced levels in IBS-C (constipation-predominant) and changes
in plasma and tissue levels of serotonin transporter protein (SERT;
Dunlop et al., 2005; Atkinson et al., 2006; Zou et al., 2007; Camil-
leri, 2011). Drugs aimed at selective modulation of the 5-HT
activity (SSRIs, 5-HT3, and 5-HT4 receptor antagonists) or both 5-
HT and norepinephrine (NE) systems (serotonin-norepinephrine
reuptake inhibitors, SNRIs, and tricyclic antidepressants, TCAs)
have been used in the treatment of functional GI disorders, as
well as in other chronic pain conditions, and psychiatric syn-
dromes. New generation drugs with similar pharmacological pro-
file may soon become novel efficient therapeutics in the treatment
of IBS.
Several large clinical trials have demonstrated that serotonin
receptor 5-HT3R antagonists, like alosetron, cilansetron, and
ramosetron are among the most effective therapeutic options
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to date for both male and female IBS-D patients (Jarcho et al.,
2008, and citations therein). The 5-HT3R antagonists alleviate spe-
cific IBS symptoms, such as frequent bowel movements, feelings
of urgency, and chronic abdominal pain and discomfort, acting
through central and peripheral mechanisms. Although the precise
mechanisms underlying their effectiveness remain incompletely
understood, symptom improvement associated with an interac-
tion with dopamine, cholecystokinin, glutamate, acetylcholine,
and GABA (for review see, Barnes et al., 2009) and a reduction
in amygdala and emotional arousal circuit activity (Berman et al.,
2002) have been suggested. Inhibition of the spinal cord c-fos
expression by 5-HT3R antagonists in response to noxious CRD
(Kozlowski et al., 2000) suggests that 5-HT3R plays a role in the
transmission of noxious information within the spinal cord. Excess
5-HT released from enterochromaffin cells (EC) in the colonic
mucosa of both unselected and PI-IBS patients (Spiller, 2007)
and decreased expression of SERT (Coates et al., 2004) may also
account to this phenomenon.
5-HT3 antagonist-based therapies require the implementation
of a risk management plan, as ischemic colitis and complica-
tions of constipation may occur (Chang et al., 2010). Therefore, a
novel class of compounds (of which the prototype is LX-1031) is
being developed that directly inhibits 5-HT synthesis in EC cells,
potentially reversing the underlying pathogenetic factor in con-
ditions like IBS-D. Such compounds could become an alternative
to the application of classical 5-HT3 receptor antagonists in the
treatment of IBS.
Recently, partial 5-HT1 receptor agonists, like buspirone, and
antagonists, like robalzotan tartrate monohydrate (AZD7371),
attracted much attention as they displayed a potent analgesic effect
in the CRD-induced visceral pain model in rats (Sivarao et al.,
2004; Lindstrom et al., 2009). However, the clinical development
of AZD7371 has been discontinued due to severe adverse events,
including hallucinations and the inability to demonstrate signif-
icant efficacy in IBS patients compared with placebo (Drossman
et al., 2008).
The 5-HT4 receptors in the GI tract are found on enteric neu-
rons and smooth muscle cells. Stimulation of 5-HT4 receptors
leads to acetylcholine release and prokinetic effects (Gershon and
Tack, 2007). The early generation 5-HT4 receptor agonists, such
as cisapride and tegaserod, reversed slow motility and relieved
constipation, but they have been withdrawn because of cardiac
or vascular adverse effects (Gershon and Tack, 2007). A number
of novel 5-HT4 agonists have recently been obtained as potential
treatments for patients with IBS-C and appear to be safer than
earlier generation agents in these classes (Camilleri et al., 2008;
Manini et al., 2010).
The 5-HT7 and 5-HT2B receptors are yet another potential
serotonergic target for future IBS treatment. The 5-HT7 recep-
tors are present in humans and other animals and are linked with
depression, circadian rhythm, neuroendocrine function, affective
behavior and body temperature regulation (for review see, Van-
hoenacker et al., 2000). They play an important role in regulating
smooth muscle relaxation in the GI and nociceptive pathways
(Carter et al., 1995; Meuser et al., 2002) and may thus be involved
in the pathological mechanisms of GI dyskinesia, abdominal pain,
and visceral paresthesia in IBS. It was demonstrated that 5-HT7
receptors also mediate stress and glucocorticoid-induced effects on
hippocampal neurogenesis, which have been implicated in mood.
Meanwhile, 5-HT2B receptor blockade was shown to reduce sig-
nificantly pain behaviors in response to CRD (O’Mahony et al.,
2010a).
Recent studies demonstrated that serotonergic neurotransmis-
sion can be markedly affected by CRF acting in a CRF receptor-
dependent manner (Cryan et al., 2005; Valentino and Commons,
2005). The injection of low doses of CRF in the dorsal raphe
nucleus (DRN) reduced the discharge rate of serotonergic neurons
in the striatum (Kirby et al., 2000) and the nucleus accumbens
(Lukkes et al., 2008) and at a higher dose increased striatal 5-
HT release (Price et al., 1998). Additionally, 5-HT levels in the
hippocampus were increased by i.c.v. administration of low and
high doses of CRF (Penalva et al., 2002). These data suggest a
close correlation between the serotonergic system and CRF, which
may be taken into consideration when novel anti-IBS therapies are
designed.
BENZODIAZEPINE RECEPTORS
One of the newly targeted classes of drugs for the treatment of vis-
ceral pain are benzodiazepine (BZD) receptor modulators. BZD
receptors are located in subcortical and hypothalamic regions
and appear important in controlling autonomic function, such
as motor and sensory activity of the gut (for review see, Salari
and Abdollahi, 2011). In addition, activation of the central BZD
receptors affects GABA interaction with central GABA-A recep-
tors and may influence the ANS, dorsal vagal nuclei, and the ENS.
Peripheral BZD receptors were identified on immune cells and
other peripheral tissues and may be involved in cell proliferation
and immunomodulation (for review see, Zisterer and Williams,
1997).
The BZD receptors and their ligands, which belong to an impor-
tant regulatory network between the CNS, behavior, and immune
response, may thus become an attractive target for future IBS treat-
ments. Recently, a novel BZD receptor ligand dextofisopam was
developed for the management of IBS-D (Grundmann et al., 2010)
and is currently under investigation.
NEUROKININ RECEPTORS
Substance P (SP) and the neurokinin-1 receptors (NK1R)
are located throughout the BGA, including peripheral, spinal,
supraspinal, and cortical sites of visceral afferent pathways, as
well as brain regions involved in emotional arousal and auto-
nomic function (Tillisch et al., 2012, and citations therein). It
was observed that SP and NK1R signaling play an important role
in nociceptive responses (hyperalgesia) and the autonomic and
behavioral responses to stress in animals and humans.
Recent study by Tillisch et al. (2012) revealed that a 3-week
treatment with a novel NK1R antagonist reduced activation of
key regions of both the interoceptive afferent and emotional
arousal network in response to noxious and non-noxious vis-
ceral stimulus in female IBS patients, causing a large decrease
in pain-induced negative affect and decreased anxiety and pain
ratings. This positive correlation suggests a potential for use
of NK1R antagonists in IBS patients to decrease pain related
distress.
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BRAIN-DERIVED NEUROTROPHIC FACTOR
Neurotrophins promote neuronal survival along with the growth
and differentiation of new neurons and synapses. Brain-derived
neurotrophic factor (BDNF) may be involved in the integration
of excitatory and inhibitory neurotransmission and emerging evi-
dence suggests that amygdaloid BDNF can regulate anxiety-like
behaviors (Slack et al., 2004; Pandey et al., 2006).
Yu et al. (2012) recently observed a significant upregulation of
BDNF in the colonic mucosa and structural alterations of mucosal
innervation in biopsies from patients with IBS, as compared with
controls. The enhanced expression of BDNF was closely correlated
with the degree of abdominal pain in IBS. These results suggest
that endogenous BDNF released in response to inflammation con-
tributes to the development of central sensitization and thus plays
a pathophysiological role in the altered gut sensation in IBS. Fur-
thermore, the upregulation of BDNF may also play a role in the
structural alterations of mucosal nerve fibers in patients with IBS.
Inhibition of the BDNF system could therefore be beneficial for
the alleviation of symptoms in the IBS patients.
SEX STEROID RECEPTORS
Because of the sex differences in perceptual responses and a female
predominance of the disorder, attention has been drawn to the
role of sex steroids, in particular ovarian hormones, in the devel-
opment of IBS. Previous reports revealed that women with IBS
often report exacerbation of symptoms, including visceral and
somatic sensitivity during menses (Kane et al., 1998; Mayer et al.,
1999; Houghton et al., 2002; Chang et al., 2006; Gustafsson and
Greenwood-Van, 2011) and show greater, compared to men, acti-
vation of brain areas associated with affective responses including
the amygdala and cingulate cortex (Berman et al., 2000; Naliboff
et al., 2003). In contrast, male IBS patients show less visceral
hypersensitivity than female patients, but have greater sympa-
thetic nervous system responses measured by skin conductance,
and decreased cardiovagal activity measured by heart rate vari-
ability compared to female IBS patients (Tillisch et al., 2005) and
male controls.
Although ovarian steroid receptor levels are higher in some
regions of the female brain (Greco et al., 2001; Milner et al., 2008),
progesterone and estradiol-induced visceral hypersensitivity does
not appear to be sex specific, as males also showed increased vis-
ceral sensitivity following hormone implantation on the amygdala
(Myers et al., 2011). However, the amygdala may still represent the
key supraspinal site mediating the actions of ovarian hormones
on visceral pain in both males and females and account for dif-
ferences in symptom generation in male and female IBS patients
(Naliboff et al., 2003; Labus et al., 2008; Kilpatrick et al., 2010).
The amygdala may thus become an interesting target for the IBS
treatment and alleviation of pain.
TOLL-LIKE RECEPTORS
Toll-like receptors (TLRs) have been localized on mucosal sur-
faces, including the colonic epithelial cells, and their expression is
increased in the colonic mucosa of rat models of visceral hypersen-
sitivity and mucosal biopsies from IBS patients (McKernan et al.,
2009; Brint et al., 2011). TLRs are activated by various bacter-
ial and viral cell components (Takeuchi and Akira, 2010), which
stimulate transcription of inflammatory cytokines, like IL-1b, IL-6,
and TNFa and affect transmission in the spinal cord, resulting in
central sensitization and hyperalgesia (for review seel, Akira and
Takeda, 2004; Arebi et al., 2008). Cytokines are also known to cross
the blood-brain barrier, to affect the HPA axis and stress response
and to stimulate secretion of CRH in rat, as well as in humans (for
review see, John and Buckingham, 2003; Dantzer et al., 2008).
Recently, McKernan et al. (2011) demonstrated that TLR
agonist-induced cytokine and cortisol release was markedly
enhanced in stimulated whole blood from IBS patients compared
with healthy controls. These results point out at the TLR as possible
targets in the treatment of IBS.
RECEPTORS FOR ACETYLCHOLINE AND CATECHOLAMINES
There is an increasing evidence for the beneficiary role of cholin-
ergic, dopaminergic, and noradrenergic pathways in regulating
immunity and cytokine production in IBS, suggesting a posi-
tive influence of acetylcholine and catecholamines on the IBS
symptoms (Dinan et al., 2008; Rosas-Ballina and Tracey, 2009).
However, adrenaline was shown to act directly through adrener-
gic receptors on DRG neurons or indirectly by increasing levels
of pronociceptive mediators following immune activation in the
colon or repeated stress, thus increasing the excitability of the neu-
rons and exacerbating pain sensation (Khasar et al., 2008; Winston
et al., 2010; Ibeakanma et al., 2011). In contrast, no significant
differences in NE responses to sigmoidoscopy were observed in
women with IBS-D compared to healthy women (Chang et al.,
2009).
These conflicting results point at the necessity of further studies
on the involvement of cholinergic, dopaminergic, and adrener-
gic receptors and their ligands in development of IBS and their
possible therapeutical application.
PAST, PRESENT, AND FUTURE OF ANTI-IBS DRUGS
TARGETING THE BRAIN-GUT AXIS
For most IBS patients with mild symptoms, lifestyle, and dietary
changes may be sufficient; for more moderate symptoms, medica-
tions that act on the gut (e.g., anticholinergics, peripheral 5-HT
agents) can be considered. However, patients who suffer from
severe IBS, characterized by increased levels of pain, poorer quality
of life, psychosocial difficulties, or co-morbidity with mood dis-
turbances are usually refractory to first- and second-line therapies
(Drossman et al., 2000; Grover and Drossman, 2011). The bi-
directional communication between the brain and the gut opens
up new treatment possibilities for these patients and directs us to
novel pharmacological targets for the anti-IBS drugs.
Almost all IBS patients could benefit from centrally acting
treatments, like therapies focused on teaching better stress cop-
ing strategies, both at a cognitive and behavioral level (for review
see, Larauche et al., 2012), or psychotropic agents. Some of the
TCAs, SSRIs, SNRIs, or BZDs have already been employed in the
treatment of IBS and proved effective in symptom relief via mood
stabilization, modulation of pain perception and amelioration of
GI motility and secretion (Ford et al., 2009; Grover and Drossman
(2011) estimate that at least every one in eight patients with IBS
is offered an antidepressant). However, the effects of psychotropic
agents on bowel symptoms and visceral hypersensitivity in IBS
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patients have been less robust and less consistent than the benefits
reported for global symptoms and abdominal pain/discomfort
(Chey et al., 2011). Furthermore, psychotropic agents are not free
from undesired side effects. TCAs display anticholinergic prop-
erties, including constipation, tachycardia, urinary retention, and
xerostomia; patients may also encounter central side effects includ-
ing sedation, insomnia, agitation, and nightmares (Chey et al.,
2011). Compared to TCAs, SSRIs have fewer side effects, but do
not improve bloating or visceral pain (Tack et al., 2006). BZDs
are used routinely in anxiety disorders, but their efficacy in symp-
tom relief of IBS is under debate (Drossman et al., 2002). New
generation of psychotropic agents is therefore anticipated.
Efficacious and safe serotonergic agents may also become future
drugs in the treatment of IBS. Recently, novel mixed 5-HT1A
agonists/5-HT3 antagonists, 5-HT1B/D agonists, and 5-HT2B
antagonists have been proposed as new therapeutics for IBS (Tack
et al., 2000; Mulak and Paradowski, 2006; Vera-Portocarrero et al.,
2008; Asagarasu et al., 2009; O’Mahony et al., 2010b).
Other endogenous systems, which may become possible new
targets in the IBS therapy, include GABA-B, CRF, NK, cannabi-
noid, and opioid receptors and their ligands. Preliminary data
suggest that anxiolytic activity of GABA-ergic agent, gabapentin
may be efficient in reducing central sensitization in hyperalge-
sia (for review see, Camilleri and Andresen, 2009). CRF receptor
antagonists have also been proposed as a potential treatment of
IBS (Martinez and Tache, 2006; Tache et al., 2009). However, due
the failure of treatment with a CRFR1 antagonists to alter colonic
transit and the global improvement scale in IBS patients (Sweetser
et al., 2009), further studies are required.
The potential use of cannabinoid and opioid receptor ligands
as anti-IBS agents has also been considered and has been reviewed
in detail elsewhere (Fichna et al., 2009; Izzo and Sharkey, 2010).
CONCLUSION
In summary, there is striking evidence of a crucial involvement
of the BGA in the development of IBS and IBS like symptoms.
Though the role of the BGA is not fully understood, some con-
cepts are at an advanced stage and allow speculation on possi-
ble future treatment options. Future research needs to identify
the exact involvement of the discussed neurotransmitter systems
and to identify at which level pharmacological treatment may be
beneficial to patients with IBS.
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